On ECHEMI
Home > Drugs > Bowel cancer
Bowel cancer
Intestinal cancer (carcinoma of rectum) is a common malignant tumor in the gastrointestinal tract. Its incidence rate is second only to stomach and esophageal cancer. It is the most common part of colorectal cancer (accounting for about 60%). The vast majority of patients are over 40 years old, and about 15% are under 30 years old. It is more common in men, with a male-to-female ratio of 2-3:1. Intestinal cancer should be actively prevented.
Related Drugs
Lomustine Capsules
Indication: This product is highly lipid-soluble and can pass through the blood-brain barrier and enter the cerebrospinal fluid. It is often used for primary brain tumors (such as glioblastoma) and secondary tumors; for the treatment of solid tumors, such as combination therapy for gastric cancer, colorectal cancer, bronchial lung cancer, malignant lymphoma, etc.
Manufacturer:

Jilin Jiatai Pharmaceutical Co., Ltd.

Lomustine Capsules
Manufacturer:

ZHONGFU Pharmaceutical Co., Ltd.

Lomustine Capsules
Indication: This product is highly lipid-soluble and can pass through the blood-brain barrier and enter the cerebrospinal fluid. It is often used for primary brain tumors (such as glioblastoma) and secondary tumors; for the treatment of solid tumors, such as combination therapy for gastric cancer, colorectal cancer, bronchial lung cancer, malignant lymphoma, etc.
Manufacturer:

ZHONGFU Pharmaceutical Co., Ltd.

Lomustine Capsules
Indication: This product is highly lipid-soluble and can pass through the blood-brain barrier and enter the cerebrospinal fluid. It is often used for primary brain tumors (such as glioblastoma) and secondary tumors; for the treatment of solid tumors, such as combination therapy for gastric cancer, colorectal cancer, bronchial lung cancer, malignant lymphoma, etc.
Manufacturer:

Harbin Pharmaceutical Group Co., Ltd. GENERAL Pharm. FACTORY

Lomustine Capsules
Indication: This product is highly lipid-soluble and can pass through the blood-brain barrier and enter the cerebrospinal fluid. It is often used for primary brain tumors (such as glioblastoma) and secondary tumors; for the treatment of solid tumors, such as combination therapy for gastric cancer, colorectal cancer, bronchial lung cancer, malignant lymphoma, etc.
Manufacturer:

ZHONGFU Pharmaceutical Co., Ltd.

Doxifluridine dispersible tablets
Indication: This product is used to treat breast cancer, gastric cancer, colon cancer, rectal cancer, and nasopharyngeal cancer.
Manufacturer:

Shandong Newtime Pharmaceutical Co., Ltd.

Uracil Tegafur Tablets
Indication: It is used for digestive tract cancers such as stomach cancer, intestinal cancer, pancreatic cancer, and can also be used for breast cancer and primary liver cancer. Taking the medicine before and after surgery may prevent the recurrence, spread, and metastasis of cancer.
Manufacturer:

Harbin Laiboten Pharmaceutical Co., Ltd.

Uracil Tegafur Tablets
Indication: It is used for digestive tract cancers such as stomach cancer, intestinal cancer, pancreatic cancer, and can also be used for breast cancer and primary liver cancer. Taking the medicine before and after surgery may prevent the recurrence, spread, and metastasis of cancer.
Manufacturer:

Qilu Pharmaceutical Co., Ltd.

Uracil Tegafur Tablets
Indication: It is used for digestive tract cancers such as stomach cancer, intestinal cancer, pancreatic cancer, and can also be used for breast cancer and primary liver cancer. Taking the medicine before and after surgery may prevent the recurrence, spread, and metastasis of cancer.
Manufacturer:

RenHe Hetero Pharmaceuticals Ltd.

Uracil Tegafur Tablets
Indication: It is used for digestive tract cancers such as stomach cancer, intestinal cancer, pancreatic cancer, and can also be used for breast cancer and primary liver cancer. Taking the medicine before and after surgery may prevent the recurrence, spread, and metastasis of cancer.
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.